The Effect of IL-6 174G > C Gene Polymorphism on Gastrointestinal Cancer: a Systematic Review and Meta-analysis

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2023 Jun 16

PMID 37324283

Authors

Niloofar Darvishi

Nader Salari

Shadi Bokaee

Shamarina Shohaimi

Masoud Mohammadi

Affiliations

Soon will be listed here.

Abstract

IL-6 gene polymorphisms can play a role in the development or control of cancer by affecting cytokines. Gastrointestinal cancer is one of the most common types of cancer worldwide. The aim of this study was to investigate the effect of polymorphism of the IL-6 174G > C gene on gastrointestinal cancers based on a systematic review and meta-analysis, including gastric, colorectal, and esophageal cancer. In this study, a systematic and meta-analytical review of the study data on the effect of polymorphism of IL-6 174G > C gene on gastrointestinal cancer (gastric, colorectal, and esophageal cancer) in Scopus, EMBASE, Web of Science, PubMed, and Science Direct Databases was extracted without any time limit until April 2020. In order to perform the analysis of eligible studies, the model of random effects was used and the heterogeneity of studies was investigated with index. Data analysis was performed with Comprehensive Meta-Analysis software (Version 2). The total number of surveyed studies in patients with colorectal cancer was 22 studies. Based on the results of meta-analysis, the odds ratio of GG genotype in patients with colorectal cancer was 0.88. The odds ratio of GC genotype obtained in patients with colorectal cancer was 0.88 and the odds ratio of CC genotype in patients with colorectal cancer was 0.92. The total number of surveyed studies in patients with gastric cancer was 12. Based on the meta-analysis results, the odds ratio of GG genotype in patients with gastric cancer was 0.74, the odds ratio of GC genotype in patients with gastric cancer was 1.27, and the odds ratio of CC genotype in patients with gastric cancer was 0.78. The total number of surveyed studies in esophageal cancer patients was 3 studies. Based on the results of meta-analysis, the odds ratio of GG genotype in patients with esophageal cancer was 0.57, the odds ratio of GC genotype in patients with esophageal cancer was 0.44, and the odds ratio of chance of CC genotype in patients with esophageal cancer was 0.99. In general, different genotypes of polymorphism of the IL-6 174G > C gene reduce the risk of gastric, colorectal, and esophageal cancer. However, the GC genotype of this gene was associated with a 27% increased risk of gastric cancer.

References

Sugimoto M, Yamaoka Y, Furuta T . Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol. 2010; 16(10):1188-200. PMC: 2839170. DOI: 10.3748/wjg.v16.i10.1188. View

Claassen Y, van Amelsfoort R, Hartgrink H, Dikken J, de Steur W, van Sandick J . Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial. Ann Surg. 2018; 270(6):1096-1102. DOI: 10.1097/SLA.0000000000002940. View

Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A . Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol. 2006; 14(2):329-39. DOI: 10.1245/s10434-006-9122-9. View

Gautam K, Muktanand T, Sankhwar S, Goel A, Sankhwar P, Rajender S . Functional polymorphisms in the IL6 gene promoter and the risk of urinary bladder cancer in India. Cytokine. 2015; 77:152-6. DOI: 10.1016/j.cyto.2015.11.008. View

Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X . Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 2016; 7(2):232-7. PMC: 4773307. DOI: 10.1111/1759-7714.12322. View

Vogel U, Christensen J, Dybdahl M, Friis S, Hansen R, Wallin H . Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007; 624(1-2):88-100. DOI: 10.1016/j.mrfmmm.2007.04.006. View

Ouyang Y, Li Y, Huang Y, Li X, Zhu Y, Long Y . CircRNA circPDSS1 promotes the gastric cancer progression by sponging miR-186-5p and modulating NEK2. J Cell Physiol. 2018; 234(7):10458-10469. DOI: 10.1002/jcp.27714. View

El-Omar E, Rabkin C, Gammon M, Vaughan T, Risch H, Schoenberg J . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003; 124(5):1193-201. DOI: 10.1016/s0016-5085(03)00157-4. View

Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Colman H, Le Neel T . Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer. 2008; 8:326. PMC: 2585099. DOI: 10.1186/1471-2407-8-326. View

10.

Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J . Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003; 63(13):3560-6. View

11.

Kim D, Oh S, Kwon H, Lee S, Kwon K, Kim B . Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9:155. PMC: 2694817. DOI: 10.1186/1471-2407-9-155. View

12.

Kamangar F, Abnet C, Hutchinson A, Newschaffer C, Helzlsouer K, Shugart Y . Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control. 2006; 17(1):117-25. DOI: 10.1007/s10552-005-0439-7. View

13.

Du H, Yang J, Zhang Y . Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer. BMC Cancer. 2020; 20(1):357. PMC: 7189715. DOI: 10.1186/s12885-020-06860-y. View

14.

Gunter M, Canzian F, Landi S, Chanock S, Sinha R, Rothman N . Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(6):1126-31. DOI: 10.1158/1055-9965.EPI-06-0042. View

15.

Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A . Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008; 29(6):1202-6. DOI: 10.1093/carcin/bgn101. View

16.

Tsilidis K, Helzlsouer K, Smith M, Grinberg V, Hoffman-Bolton J, Clipp S . Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009; 20(9):1739-51. PMC: 4119174. DOI: 10.1007/s10552-009-9427-7. View

17.

Basavaraju U, Shebl F, Palmer A, Berry S, Hold G, El-Omar E . Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2014; 24(4):296-304. PMC: 4411199. DOI: 10.1097/CEJ.0000000000000087. View

18.

Jafari-Nedooshan J, Dastgheib S, Kargar S, Zare M, Raee-Ezzabadi A, Heiranizadeh N . Association of IL-6 -174 G>C Polymorphism with Susceptibility to Colorectal Cancer and Gastric Cancer: a Systematic Review and Meta-Analysis. Acta Medica (Hradec Kralove). 2020; 62(4):137-146. DOI: 10.14712/18059694.2020.2. View

19.

Arnold M, Park J, Camargo M, Lunet N, Forman D, Soerjomataram I . Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020; 69(5):823-829. PMC: 8520492. DOI: 10.1136/gutjnl-2019-320234. View

20.

Talseth B, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott R . Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2007; 42(5):628-32. DOI: 10.1080/00365520601106699. View